S. Perez

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

S. Peters, J. Soria, A. Stathis, 2016 .

Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.

K. Small, P. Ghia, L. Scarfò, 2017, Blood.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

S. Peters, J. Soria, A. Stathis, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).

M. Sanson, O. Chinot, A. Hottinger, 2016 .

Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).

D. Hafler, H. Friedman, D. Reardon, 2014 .